1. National Prescribing Indicator
Biosimilars
National Prescribing Indicator

2. Introduction A biosimilar medicine is: -
“a biological medicine that is developed to be highly similar and clinically equivalent to an existing biological medicine”.
Biosimilar medicines are different to generic medicines because?
Biological medicines including all biosimilars must be prescribed by brand name (MHRA) to support Pharmacovigilance mhra.gov.uk/yellowcard

3. Introduction A biosimilar medicine is: -
“a biological medicine that is developed to be highly similar and clinically equivalent to an existing biological medicine”.
Biosimilar medicines are different to generic medicines because?
Biological medicines including all biosimilars must be prescribed by brand name (MHRA) to support Pharmacovigilance mhra.gov.uk/yellowcard

4. Biosimilar work streams
National Prescribing Indicators
Biosimilar dashboard (cost efficiency work)

5. National Prescribing Indicators

6. National Prescribing Indicator process

7. Biologics spending

8. Biologics spending

9. Biosimilar National Prescribing Indicator
Why have an National prescribing indicator looking at biosimilars?
Continuing development of biological medicines, including biosimilar medicines, creates: -
- increased choice for patients and clinicians
- increased commercial competition
- possible enhanced value propositions for individual medicines
- support the treatment of an increasing number of patients and the uptake of new and innovative medicines

10. Biosimilar National Prescribing Indicator
Why have an National prescribing indicator looking at biosimilars?
Continuing development of biological medicines, including biosimilar medicines, creates: -
- increased choice for patients and clinicians
- increased commercial competition
- possible enhanced value propositions for individual medicines
- support the treatment of an increasing number of patients and the uptake of new and innovative medicines

11. Biosimilar National Prescribing Indicator – the history
First introduced in
Unit of measure: Quantity of biosimilar medicines prescribed as a percentage of total ‘reference’ product plus biosimilar.
Target: Increase the appropriate use of cost-effective biological medicines, including biosimilar medicines.
Evolving biological medicine basket

12. Quarter
Biosimilar percentages of total biologics across health boards/trust in Wales

13. Infliximab

14. Etanercept

15. Rituximab (intravenous)

16. Infliximab
94.2%

17. Etanercept
83.8%

18. Rituximab (intravenous)
96.3%

19. NHS England Infliximab Etanercept Rituximab
% uptake
NHS/Foundation Trusts ranked from lowest to highest
Etanercept
% uptake
NHS/Foundation Trusts ranked from lowest to highest
Rituximab
% uptake
NHS/Foundation Trusts ranked from lowest to highest

20. Infliximab biosimilar use as a percentage of total infliximab use
NHS Scotland
Infliximab biosimilar use as a percentage of total infliximab use
January to March 2018

21. Etanercept biosimilar use as a percentage of total etanercept use
NHS Scotland
Etanercept biosimilar use as a percentage of total etanercept use
January to March 2018

22. Rituximab biosimilar use as a percentage of total rituximab use
NHS Scotland
Rituximab biosimilar use as a percentage of total rituximab use
January to March 2018

23. Total biosimilar usage (Infliximab, etanercept and rituximab combined)
87%

30. Thank you! Further information NPIs – www.awmsg.org
> Medicines Management > National Prescribing Indicators
Biosimilar data –
> WAPSU resources > SPIRA > Biosimilar Efficiencies
Enquiries –